FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Animals (Basel) / Preliminary Study: Proteomic Profiling Uncovers Potential Pr...
Animals : an open access journal from MDPI2021; 11(7); 1913; doi: 10.3390/ani11071913

Preliminary Study: Proteomic Profiling Uncovers Potential Proteins for Biomonitoring Equine Melanocytic Neoplasm.

Abstract: Equine melanocytic neoplasm (EMN) is a cutaneous neoplasm and is mostly observed in aged grey horses. This preliminary study aimed to identify potential proteins to differentiate normal, mild and severe EMN from serum proteomic profiling. Serum samples were collected from 25 grey horses assigned to three groups: normal (free of EMN; = 10), mild ( = 6) and severe EMN ( = 9). To explore the differences in proteins between groups, proteomic profiling and analysis were employed. Accordingly, 8241 annotated proteins out of 8725 total proteins were compared between normal and EMN groups and inspected based on differentially expressed proteins (DEPs). Through DEP analysis, 95 significant DEPs differed between normal and EMN groups. Among these DEPs, 41 significant proteins were categorised according to protein functions. Based on 41 significant proteins, 10 were involved in metabolism and 31 in non-metabolism. Interestingly, phospholipid phosphatase6 (PLPP6) and ATPase subunit alpha (Na+/K+-ATPase) were considered as potential proteins uniquely expressed in mild EMN and related to lipid and energy metabolism, respectively. Non-metabolism-related proteins (BRCA1, phosphorylase B kinase regulatory subunit: PHKA1, tyrosine-protein kinase receptor: ALK and rho-associated protein kinase: ROCK1) correlated to melanoma development differed among all groups. The results of our study provide a foundation for early EMN biomonitoring and prevention.
Get Full Text
Publication Date: 2021-06-27 PubMed ID: 34199079PubMed Central: PMC8300200DOI: 10.3390/ani11071913Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses a preliminary study where scientists utilized proteomic profiling to identify unique proteins in the serum of grey horses that may indicate the presence or severity of Equine Melanocytic Neoplasm (EMN), a type of skin cancer.

Methodology

  • Scientists collected serum samples from 25 grey horses categorized based on their EMN status: normal ( = 10), mild EMN ( = 6), and severe EMN ( = 9).
  • They used proteomic profiling (analyzing the specific proteins present in the serum), and a comparative analysis, focusing on differentially expressed proteins (DEPs) to identify variations in the proteins present in the different groups.
  • Of the total of 8725 proteins analysed, 8241 were annotated and compared between the normal and EMN groups.

Findings

  • 95 significant DEPs were identified, differing between normal and EMN groups.
  • Out of these differentially expressed proteins, 41 were identified as most crucial and were classified according to their functions.
  • 10 of these proteins were involved in metabolism, and 31 were related to non-metabolic functions.
  • Two proteins, phospholipid phosphatase6 (PLPP6) and ATPase subunit alpha (Na+/K+-ATPase), were uniquely expressed in the serum of horses with mild EMN. These proteins are believed to be related to lipid and energy metabolism, respectively.
  • Non-metabolic proteins (BRCA1, phosphorylase B kinase regulatory subunit: PHKA1, tyrosine-protein kinase receptor: ALK and rho-associated protein kinase: ROCK1), were found to be linked with melanoma development, differed amongst all groups.

Conclusion

  • The results of this preliminary study provide potential markers for early biomonitoring and prevention of EMN.
  • Further studies are required to validate these findings and develop a practical diagnostic tool or preventive treatment for EMN using these biomarkers.

Cite This Article

APA
Tesena P, Kingkaw A, Vongsangnak W, Pitikarn S, Phaonakrop N, Roytrakul S, Kovitvadhi A. (2021). Preliminary Study: Proteomic Profiling Uncovers Potential Proteins for Biomonitoring Equine Melanocytic Neoplasm. Animals (Basel), 11(7), 1913. https://doi.org/10.3390/ani11071913

Publication

Animals : an open access journal from MDPI
ISSN: 2076-2615
NlmUniqueID: 101635614
Country: Switzerland
Language: English
Volume: 11
Issue: 7
PII: 1913

Researcher Affiliations

Tesena, Parichart
  • Graduate Student in Animal Health and Biomedical Science Program, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.
  • Department of Clinical Science and Public Health, Faculty of Veterinary Science, Mahidol University, Salaya, Puttamonthon, Nakhon Pathom 73170, Thailand.
Kingkaw, Amornthep
  • Interdisciplinary Graduate Program in Bioscience, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand.
  • Department of Zoology, Faculty of Sciences, Kasetsart University, Bangkok 10900, Thailand.
Vongsangnak, Wanwipa
  • Department of Zoology, Faculty of Sciences, Kasetsart University, Bangkok 10900, Thailand.
  • Omics Center for Agriculture, Bioresources, Food, and Health, Kasetsart University (OmiKU), Bangkok 10900, Thailand.
Pitikarn, Surakiet
  • Genetic Engineering and Bioinformatics Program, Graduate School, Kasetsart University, Bangkok 10900, Thailand.
Phaonakrop, Narumon
  • Functional Ingredients and Food Innovation Research Group, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani 12120, Thailand.
Roytrakul, Sittiruk
  • Functional Ingredients and Food Innovation Research Group, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani 12120, Thailand.
Kovitvadhi, Attawit
  • Department of Physiology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.

Grant Funding

  • P1950420 / Functional ingredient and Food innovation program, National Science and Technology Develop-ment Agency
  • 63 / Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 44 references
  1. Moore J, Shaw C, Shaw E, Buechner-Maxwell V, Scarratt W, Crisman M, Furr M, Roberson J. Melanoma in horses: Current perspectives. Equin Vet. Educ. 2013;25:144–151.
    doi: 10.1111/j.2042-3292.2011.00368.xgoogle scholar: lookup
  2. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms.. Vet Pathol 2002 Nov;39(6):651-78.
    doi: 10.1354/vp.39-6-651pubmed: 12450197google scholar: lookup
  3. Rosengren Pielberg G, Golovko A, Sundström E, Curik I, Lennartsson J, Seltenhammer MH, Druml T, Binns M, Fitzsimmons C, Lindgren G, Sandberg K, Baumung R, Vetterlein M, Strömberg S, Grabherr M, Wade C, Lindblad-Toh K, Pontén F, Heldin CH, Sölkner J, Andersson L. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse.. Nat Genet 2008 Aug;40(8):1004-9.
    doi: 10.1038/ng.185pubmed: 18641652google scholar: lookup
  4. Phillips JC, Lembcke LM. Equine melanocytic tumors.. Vet Clin North Am Equine Pract 2013 Dec;29(3):673-87.
    doi: 10.1016/j.cveq.2013.08.008pubmed: 24267683google scholar: lookup
  5. Valentine BA. Equine melanocytic tumors: a retrospective study of 53 horses (1988 to 1991).. J Vet Intern Med 1995 Sep-Oct;9(5):291-7.
    doi: 10.1111/j.1939-1676.1995.tb01087.xpubmed: 8531173google scholar: lookup
  6. Rieder S, Stricker C, Joerg H, Dummer R, Stranzinger G. A comparative genetic approach for the investigation of ageing grey horse melanoma. J. Anim. Breed. Genet. 2000;117:73–82.
    doi: 10.1111/j.1439-0388.2000x.00245.xgoogle scholar: lookup
  7. Seltenhammer MH, Heere-Ress E, Brandt S, Druml T, Jansen B, Pehamberger H, Niebauer GW. Comparative histopathology of grey-horse-melanoma and human malignant melanoma.. Pigment Cell Res 2004 Dec;17(6):674-81.
    doi: 10.1111/j.1600-0749.2004.00192.xpubmed: 15541026google scholar: lookup
  8. Adams DR, Ron D, Kiely PA. RACK1, A multifaceted scaffolding protein: Structure and function.. Cell Commun Signal 2011 Oct 6;9:22.
    doi: 10.1186/1478-811X-9-22pmc: PMC3195729pubmed: 21978545google scholar: lookup
  9. Desser H, Niebauer GW, Gebhart W. [Polyamine and histamine contents in the blood of pigmented, depigmented and melanoma bearing Lipizzaner horses].. Zentralbl Veterinarmed A 1980 Feb;27(1):45-53.
    doi: 10.1111/j.1439-0442.1980.tb01667.xpubmed: 6774520google scholar: lookup
  10. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent.. J Biol Chem 1951 Nov;193(1):265-75.
    doi: 10.1016/S0021-9258(19)52451-6pubmed: 14907713google scholar: lookup
  11. Johansson C, Samskog J, Sundström L, Wadensten H, Björkesten L, Flensburg J. Differential expression analysis of Escherichia coli proteins using a novel software for relative quantitation of LC-MS/MS data.. Proteomics 2006 Aug;6(16):4475-85.
    doi: 10.1002/pmic.200500921pubmed: 16858737google scholar: lookup
  12. Thorsell A, Portelius E, Blennow K, Westman-Brinkmalm A. Evaluation of sample fractionation using micro-scale liquid-phase isoelectric focusing on mass spectrometric identification and quantitation of proteins in a SILAC experiment.. Rapid Commun Mass Spectrom 2007;21(5):771-8.
    doi: 10.1002/rcm.2898pubmed: 17279600google scholar: lookup
  13. Howe EA, Sinha R, Schlauch D, Quackenbush J. RNA-Seq analysis in MeV.. Bioinformatics 2011 Nov 15;27(22):3209-10.
    doi: 10.1093/bioinformatics/btr490pmc: PMC3208390pubmed: 21976420google scholar: lookup
  14. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome.. Nucleic Acids Res 2004 Jan 1;32(Database issue):D277-80.
    doi: 10.1093/nar/gkh063pmc: PMC308797pubmed: 14681412google scholar: lookup
  15. MacGillivray KC, Sweeney RW, Del Piero F. Metastatic melanoma in horses.. J Vet Intern Med 2002 Jul-Aug;16(4):452-6.
    doi: 10.1111/j.1939-1676.2002.tb01264.xpubmed: 12141308google scholar: lookup
  16. Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, Webster MR, Kugel CH 3rd, Ecker BL, Caino MC, Kossenkov AV, Tang HY, Frederick DT, Flaherty KT, Xu X, Liu Q, Gabrilovich DI, Herlyn M, Blair IA, Schug ZT, Speicher DW, Weeraratna AT. Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2.. Cancer Discov 2020 Sep;10(9):1282-1295.
    doi: 10.1158/2159-8290.CD-20-0329pmc: PMC7483379pubmed: 32499221google scholar: lookup
  17. Rieder S, Taourit S, Mariat D, Langlois B, Guérin G. Mutations in the agouti (ASIP), the extension (MC1R), and the brown (TYRP1) loci and their association to coat color phenotypes in horses (Equus caballus).. Mamm Genome 2001 Jun;12(6):450-5.
    doi: 10.1007/s003350020017pubmed: 11353392google scholar: lookup
  18. Seltenhammer MH, Simhofer H, Scherzer S, Zechner R, Curik I, Sölkner J, Brandt SM, Jansen B, Pehamberger H, Eisenmenger E. Equine melanoma in a population of 296 grey Lipizzaner horses.. Equine Vet J 2003 Mar;35(2):153-7.
    doi: 10.2746/042516403776114234pubmed: 12638791google scholar: lookup
  19. Sundberg JP, Burnstein T, Page EH, Kirkham WW, Robinson FR. Neoplasms of Equidae.. J Am Vet Med Assoc 1977 Jan 15;170(2):150-2.
    pubmed: 576219
  20. Schlessinger J. Receptor tyrosine kinases: legacy of the first two decades.. Cold Spring Harb Perspect Biol 2014 Mar 1;6(3).
    doi: 10.1101/cshperspect.a008912pmc: PMC3949355pubmed: 24591517google scholar: lookup
  21. Seyfried TN, Shelton LM. Cancer as a metabolic disease.. Nutr Metab (Lond) 2010 Jan 27;7:7.
    doi: 10.1186/1743-7075-7-7pmc: PMC2845135pubmed: 20181022google scholar: lookup
  22. Liu J, Adhav R, Miao K, Su SM, Mo L, Chan UI, Zhang X, Xu J, Li J, Shu X, Zeng J, Zhang X, Lyu X, Pardeshi L, Tan K, Sun H, Wong KH, Deng C, Xu X. Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor.. Nat Commun 2020 Sep 25;11(1):4875.
    doi: 10.1038/s41467-020-18637-9pmc: PMC7519681pubmed: 32978388google scholar: lookup
  23. Yang WW, Wang ZH, Zhu Y, Yang HT. E2F6 negatively regulates ultraviolet-induced apoptosis via modulation of BRCA1.. Cell Death Differ 2007 Apr;14(4):807-17.
    doi: 10.1038/sj.cdd.4402062pubmed: 17096023google scholar: lookup
  24. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.. Nucleic Acids Res 2006;34(5):1416-26.
    doi: 10.1093/nar/gkl010pmc: PMC1390683pubmed: 16522651google scholar: lookup
  25. Chiarle R, Martinengo C, Mastini C, Ambrogio C, D'Escamard V, Forni G, Inghirami G. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.. Nat Med 2008 Jun;14(6):676-80.
    doi: 10.1038/nm1769pubmed: 18469826google scholar: lookup
  26. Osella-Abate S, Mereu E, Pellegrino E, Bergaggio E, Ribero S, Bertero L, Lisa F, Fierro MT, Giulio Papotti M, Piva R. ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas.. Oncol Lett 2018 Dec;16(6):7091-7096.
    doi: 10.3892/ol.2018.9560pmc: PMC6256323pubmed: 30546443google scholar: lookup
  27. Boi M, Zucca E, Inghirami G, Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.. Br J Haematol 2015 Mar;168(6):771-83.
    doi: 10.1111/bjh.13265pubmed: 25559471google scholar: lookup
  28. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, Mariamé B. Expression of the ALK tyrosine kinase gene in neuroblastoma.. Am J Pathol 2000 May;156(5):1711-21.
    doi: 10.1016/S0002-9440(10)65042-0pmc: PMC1876934pubmed: 10793082google scholar: lookup
  29. Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. Role and targeting of anaplastic lymphoma kinase in cancer.. Mol Cancer 2018 Feb 19;17(1):30.
    doi: 10.1186/s12943-018-0776-2pmc: PMC5817803pubmed: 29455642google scholar: lookup
  30. Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma?. Biochim Biophys Acta 2011 Jun;1807(6):552-61.
    doi: 10.1016/j.bbabio.2010.10.012pubmed: 20955683google scholar: lookup
  31. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect.. J Biol Chem 2011 Dec 9;286(49):42626-42634.
    doi: 10.1074/jbc.M111.282046pmc: PMC3234981pubmed: 21998308google scholar: lookup
  32. Pinheiro C, Miranda-Gonçalves V, Longatto-Filho A, Vicente AL, Berardinelli GN, Scapulatempo-Neto C, Costa RF, Viana CR, Reis RM, Baltazar F, Vazquez VL. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.. Cell Cycle 2016 Jun 2;15(11):1462-70.
    doi: 10.1080/15384101.2016.1175258pmc: PMC4934068pubmed: 27105345google scholar: lookup
  33. Gene Cards. [(accessed on 17 April 2021)]; Available online: https://www.genecards.org/
  34. Huang C, Cao Z, Ma J, Shen Y, Bu Y, Khoshaba R, Shi G, Huang D, Liao DF, Ji H, Jin J, Cao D. AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.. Mol Carcinog 2018 Oct;57(10):1300-1310.
    doi: 10.1002/mc.22844pmc: PMC6800193pubmed: 29846015google scholar: lookup
  35. Amaya CN, Mitchell DC, Bryan BA. Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growth.. BMC Cancer 2017 Jul 14;17(1):485.
    doi: 10.1186/s12885-017-3470-7pmc: PMC5513090pubmed: 28709411google scholar: lookup
  36. Human Protein Atlas. [(accessed on 26 March 2021)]; Available online: https://www.proteinatlas.org/
  37. Fernández LP, Gómez de Cedrón M, Ramírez de Molina A. Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment.. Front Oncol 2020;10:577420.
    doi: 10.3389/fonc.2020.577420pmc: PMC7655926pubmed: 33194695google scholar: lookup
  38. Pellerin L, Carrié L, Dufau C, Nieto L, Ségui B, Levade T, Riond J, Andrieu-Abadie N. Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.. Cancers (Basel) 2020 Oct 27;12(11).
    doi: 10.3390/cancers12113147pmc: PMC7692067pubmed: 33121001google scholar: lookup
  39. Fu Y, Zou T, Shen X, Nelson N, Li J, Wu C. Lipid metabolism in cancer progression and therapeutic strategies. Med Comm 2020;2:27–59.
  40. Cocco L, Follo MY, Manzoli L, Suh PG. Phosphoinositide-specific phospholipase C in health and disease.. J Lipid Res 2015 Oct;56(10):1853-60.
    doi: 10.1194/jlr.R057984pmc: PMC4583093pubmed: 25821234google scholar: lookup
  41. Amengual J, Coronel J, Marques C, Aradillas-García C, Morales JMV, Andrade FCD, Erdman JW, Teran-Garcia M. β-Carotene Oxygenase 1 Activity Modulates Circulating Cholesterol Concentrations in Mice and Humans.. J Nutr 2020 Aug 1;150(8):2023-2030.
    doi: 10.1093/jn/nxaa143pmc: PMC7398780pubmed: 32433733google scholar: lookup
  42. Levy BD, Hickey L, Morris AJ, Larvie M, Keledjian R, Petasis NA, Bannenberg G, Serhan CN. Novel polyisoprenyl phosphates block phospholipase D and human neutrophil activation in vitro and murine peritoneal inflammation in vivo.. Br J Pharmacol 2005 Oct;146(3):344-51.
    doi: 10.1038/sj.bjp.0706338pmc: PMC1440714pubmed: 16041402google scholar: lookup
  43. Lou B, Dong J, Li Y, Ding T, Bi T, Li Y, Deng X, Ye D, Jiang XC. Pharmacologic inhibition of sphingomyelin synthase (SMS) activity reduces apolipoprotein-B secretion from hepatocytes and attenuates endotoxin-mediated macrophage inflammation.. PLoS One 2014;9(7):e102641.
    doi: 10.1371/journal.pone.0102641pmc: PMC4102531pubmed: 25032960google scholar: lookup
  44. Carrié L, Virazels M, Dufau C, Montfort A, Levade T, Ségui B, Andrieu-Abadie N. New Insights into the Role of Sphingolipid Metabolism in Melanoma.. Cells 2020 Aug 26;9(9).
    doi: 10.3390/cells9091967pmc: PMC7565650pubmed: 32858889google scholar: lookup

Citations

This article has been cited 5 times.
  1. Rivolta AA, Bujold AR, Wilmarth PA, Phinney BS, Navelski JP, Horohov DW, Sanz MG. Comparison of the broncoalveolar lavage fluid proteomics between foals and adult horses. PLoS One 2023;18(9):e0290778.
    doi: 10.1371/journal.pone.0290778pubmed: 37669266google scholar: lookup
  2. Miglio A, Cremonini V, Leonardi L, Manuali E, Coliolo P, Barbato O, Dall'Aglio C, Antognoni MT. Omics Technologies in Veterinary Medicine: Literature Review and Perspectives in Transfusion Medicine. Transfus Med Hemother 2023 Jun;50(3):198-207.
    doi: 10.1159/000530870pubmed: 37408648google scholar: lookup
  3. Pimenta J, Prada J, Cotovio M. Equine Melanocytic Tumors: A Narrative Review. Animals (Basel) 2023 Jan 10;13(2).
    doi: 10.3390/ani13020247pubmed: 36670786google scholar: lookup
  4. Tesena P, Kingkaw A, Phaonakrop N, Roytrakul S, Limudomporn P, Vongsangnak W, Kovitvadhi A. Faecal Proteomics and Functional Analysis of Equine Melanocytic Neoplasm in Grey Horses. Vet Sci 2022 Feb 21;9(2).
    doi: 10.3390/vetsci9020094pubmed: 35202347google scholar: lookup
  5. Tesena P, Vinijkumthorn R, Kingkaw A, Yanyongsirikarn P, Phasuk K, Ploypetch S, Phaonakrop N, Roytrakul S, Vongsangnak W, Prapaiwan N. Probing Wnt pathway and functional signal in equine melanocytic neoplasms through quantitative proteomics and immunohistochemistry. BMC Vet Res 2025 Aug 7;21(1):509.
    doi: 10.1186/s12917-025-04956-wpubmed: 40775356google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.